Adding 177Lu-PSMA-617 to combination therapy improves disease control in PSMA+ mHSPC while maintaining quality of life and ...
SABRE project leads discuss landmark changes in total hip BMD as a surrogate for fracture risk reduction in postmenopausal osteoporosis.
The consensus marks a sequential improvement from the third quarter, when Amneal earned $0.17 per share on revenue of $785 million. Investors will scrutinize whether the Bridgewater, N.J.-based ...
Researchers conducted a retrospective cohort study using data from the TriNetX US Collaborative Network to compare the risk for incident OA in adults with osteoporosis treated with denosumab vs ...
Treatment strategies after denosumab discontinuation in non-metastatic breast cancer treated with AI
Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...
Amgen Inc (AMGN) reports robust sales growth with 14 blockbuster products, while navigating competitive pressures and strategic pivots.
The Women’s Health Initiative study in 2002 had a lasting negative effect on the use of menopausal hormone therapy (MHT), which combines estrogen with medroxyprogesterone acetate (MPA). Although the ...
Feb 5 (Reuters) - (This Feb 5 story has been corrected to fix Prolia's 2025 sales to $4.4 billion, not $1.05 billion, in paragraph 5) Sign up here. Its pharmacy benefit management unit, Caremark, will ...
Biosimilar Ranluspec is used to treat neovascular (wet) age-related macular degeneration and other retinal vascular disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results